Form 4: SpringWorks Therapeutics Director Daniel Lynch Sells Shares

Director Daniel Lynch sold shares of SpringWorks Therapeutics (SWTX) on February 20, 2025, under a pre-arranged trading plan.

Summary

• Daniel Lynch, a director of SpringWorks Therapeutics, sold shares of the company's common stock on February 20, 2025.
• The sales were executed under a trading plan pursuant to Rule 10b5-1.
• A total of 44,018 shares were sold at a weighted average price of $60.1387, with prices ranging from $60.00 to $60.68.
• An additional 3,582 shares were sold at a weighted average price of $61.2364, with prices ranging from $61.16 to $61.45.
• Following the transactions, Mr. Lynch directly owns 82,944 shares of SpringWorks Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine Form 4 filing related to pre-planned stock sales. There's no indication of positive or negative sentiment towards the company's future prospects.

Industry Context

Insider sales are a common occurrence and are often related to personal financial planning rather than a negative outlook on the company. However, significant or unusual insider selling activity can sometimes be viewed negatively by investors.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, particularly if investors are not aware of the pre-arranged trading plan.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Daniel Lynch, stock sale, Form 4, insider trading, Rule 10b5-1, director